Rescue Therapy for Helicobacter Pylori Infection
Key facts
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 360 people enrolled
- Started
- 16 May 2023
- Ended
- 31 Jan 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan
- Bismuth Potassium Citrate
- Tetracycline
- Metronidazole
- Amoxicillin
- Rifabutin
- Record updated
- 15 September 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Ability and willingness to participate in the study and to sign and give informed consent
- Confirmed H. pylori infection and with previous treatment experience
Who cannot take part
- Previous history of tuberculosis
- administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
- history of gastrectomy
- Allergy to any of the study drugs
- severe systemic diseases or malignancy
- under 18 or over 80 years old
- subjects naive to H. pylori treatment,
- pregnant or lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Dual therapy containing vonoprazan and amoxicillin had showed excellent eradication results with Helicobacter pylori first-line treatment. However, no study has examined its efficacy for H. pylori rescue treatment. Rifabutin has low antibiotic resistance, superior antibacterial activity in vitro, and stability in the gastric acid environment. Several studies have confirmed the efficacy of rifabutin-containing triple therapy as a first-line or rescue treatment for H. pylori. The purpose of this study was to evaluate the efficacy and safety of dual therapy vesus rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori.
The 3 groups in the trial
- Tetracycline Bismuth Quadruple TherapyExisting treatment, for comparison
Vonoprazan 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
Treatment: Vonoprazan, Bismuth Potassium Citrate, Tetracycline, and Metronidazole
- Rifabutin Triple TherapyTreatment being tested
Vonoprazan 20mg bid, amoxicillin 1000mg tid, rifabutin 150mg bid
Treatment: Vonoprazan, Amoxicillin, and Rifabutin
- Dual TherapyTreatment being tested
Vonoprazan 20mg bid, amoxicillin 1000mg tid
Treatment: Vonoprazan and Amoxicillin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Rifabutin-containing Triple Therapy for Helicobacter Pylori Rescue Treatment: a Randomized Controlled Trial
- Publications
- Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial.The Lancet regional health. Western Pacific, 2026
- Record updated
- 15 September 2025